|
|
Post by JHam on Dec 2, 2014 14:21:32 GMT
It felt weird not getting a PR from ONCS yesterday. Rest assured they would not let that happen today  ir.oncosec.com/company-news/detail/1664OncoSec Medical Collaborates with PerkinElmer and University of California, Los Angeles to Evaluate Patient-Selection Biomarker in Immunotherapy |
|
|
|
Post by jckrdu on Dec 2, 2014 14:32:51 GMT
It felt weird not getting a PR from ONCS yesterday. Rest assured they would not let that happen today ir.oncosec.com/company-news/detail/1664OncoSec Medical Collaborates with PerkinElmer and University of California, Los Angeles to Evaluate Patient-Selection Biomarker in Immunotherapy They really seem to be focused on Merck/Keytruda and turning non-responders into responders. Setting themselves up to be a very valuable partner or aquisition target for Merck. |
|
|
|
Post by hophead on Dec 2, 2014 14:39:48 GMT
I decided to dabble here and bought a little around 0.65. Fingers crossed some great news comes out this week...
|
|
|
|
Post by JHam on Dec 2, 2014 14:55:25 GMT
It felt weird not getting a PR from ONCS yesterday. Rest assured they would not let that happen today ir.oncosec.com/company-news/detail/1664OncoSec Medical Collaborates with PerkinElmer and University of California, Los Angeles to Evaluate Patient-Selection Biomarker in Immunotherapy They really seem to be focused on Merck/Keytruda and turning non-responders into responders. Setting themselves up to be a very valuable partner or aquisition target for Merck. I really think the combination approach is where they are headed. I won't go as far as to say that is all that really matters for ONCS, but this is clearly what they are putting most of their resources towards. |
|
|
|
Post by JHam on Dec 2, 2014 14:58:05 GMT
I decided to dabble here and bought a little around 0.65. Fingers crossed some great news comes out this week... My first buy was at around $.65. I averaged way down since then, but obviously felt at the time I bought that it was undervalued at $.65. I still feel that way. |
|
madamemagoo
Junior Member
don't shoot mandy magoo!
Posts: 70 
|
Post by madamemagoo on Dec 2, 2014 15:08:17 GMT
I bought in at .42 (thanks JHam  .) Added some yesterday. |
|
|
|
Post by hophead on Dec 2, 2014 15:10:22 GMT
looks like I will averaging down as usual. Seems that there is some info coming out his week though right?
|
|
|
|
Post by JHam on Dec 2, 2014 17:12:08 GMT
looks like I will averaging down as usual. Seems that there is some info coming out his week though right? hop, there is major info coming out this week on Thursday and Friday. They are announcing new trial data on two separate trials at a huge conference in Italy to which they were invited and where both data sets were selected as "best abstract" by the conference committee. We should be getting two separate PR's for those events imo, before they happen. They also have Phase 2 MCC interim data to release, plus the announcement of a new indication, all by year's end. Things are going to remain busy with this company for the rest of this year. |
|
|
|
Post by JHam on Dec 2, 2014 17:13:15 GMT
I bought in at .42 (thanks JHam .) Added some yesterday. Wow, nice low average. Mine is $.46 so I am not complaining. |
|
|
|
Post by happyjawa on Dec 2, 2014 17:21:19 GMT
It felt weird not getting a PR from ONCS yesterday. Rest assured they would not let that happen today ir.oncosec.com/company-news/detail/1664OncoSec Medical Collaborates with PerkinElmer and University of California, Los Angeles to Evaluate Patient-Selection Biomarker in Immunotherapy I think you helped break Monday's news over the weekend. You're just being greedy. :-) |
|
|
|
Post by hophead on Dec 2, 2014 18:36:46 GMT
looks like I will averaging down as usual. Seems that there is some info coming out his week though right? hop, there is major info coming out this week on Thursday and Friday. They are announcing new trial data on two separate trials at a huge conference in Italy to which they were invited and where both data sets were selected as "best abstract" by the conference committee. We should be getting two separate PR's for those events imo, before they happen. They also have Phase 2 MCC interim data to release, plus the announcement of a new indication, all by year's end. Things are going to remain busy with this company for the rest of this year. Yeah, I'm banking on these PRs to give me at least a 20% gain from here i hope if not more. Thanks for the continued info... |
|
.) Added some yesterday.
